Pomalidomide plus Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

被引：0

作者：

Weisel, Katja ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

Cavo, Michele ^{[3
]}

Ocio, Enrique M. ^{[4
]}

Palumbo, Antonio ^{[5
]}

Corradini, Paolo ^{[6
]}

Delforge, Michel ^{[7
]}

Oriol, Albert ^{[8
]}

Goldschmidt, Harmut ^{[9
]}

Conticello, Concetta ^{[10
]}

Vacca, Angelo ^{[11
]}

Hansson, Markus ^{[12
]}

Miller, Neil ^{[13
]}

Peluso, Teresa ^{[13
]}

Sternas, Lars ^{[14
]}

Zaki, Mohamed H. ^{[14
]}

Moreau, Philippe ^{[15
]}

机构：

[1] Univ Tubingen Hosp, Tubingen, Germany

[2] Univ Athens, Sch Med, GR-11527 Athens, Greece

[3] Univ Bologna, Sch Med, Bologna, Italy

[4] Hosp Univ Salamanca IBSAL, Salamanca, Spain

[5] Univ Turin, Myeloma Unit, Div Hematol, Turin, Italy

[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[9] Univ Clin Heidelberg, Heidelberg, Germany

[10] Univ Catania, Sch Med, Catania, Italy

[11] Univ Bari, Sch Med, Bari, Italy

[12] Lund Univ, Skane Univ Hosp, Lund, Sweden

[13] Celgene Corp, Boudry, Switzerland

[14] Celgene Corp, Summit, NJ USA

[15] Univ Hosp Nantes, Nantes, France

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI)
Matous, Jeffrey
Siegel, David Samuel DiCapua
Duong, Hien Kim
Kasserra, Claudia
Sternas, Lars
Jacques, Christian
Klesczewski, Kenneth
Zaki, Mohamed H.
Shah, Jatin J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[32] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Chen, Christine I.
Sutherland, Heather J.
Kotb, Rami
Sebag, Michael
White, Darrell J.
Bensinger, William
Gasparetto, Cristina J.
Leblanc, Richard
Venner, Christopher P.
Lentzsch, Suzanne
Schiller, Gary J.
Lipe, Brea
Del Col, Aldo
Shah, Jatin J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Kauffman, Michael G.
Shacham, Sharon
Bahlis, Nizar
BLOOD, 2018, 132
[33] IMPACT OF STABLE DISEASE AS A RESPONSE TO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE ON SURVIVAL OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE MM-003 TRIAL
Moreau, P.
Weisel, K.
Song, K.
Gibson, C.
Saunders, O.
Sternas, L.
Hong, K.
Zaki, K.
Dimopoulos, M. A.
HAEMATOLOGICA, 2015, 100 : 312 - 312
[34] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
Dimopoulos, MA
Spencer, A
Attal, M
Prince, M
Harousseau, JL
Dmoszynska, A
Yu, ZU
Olesnyckyj, M
Zeldis, J
Knight, R
BLOOD, 2005, 106 (11) : 6A - 7A
[35] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth C.
BLOOD, 2022, 140
[36] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2017, 130 (10) : 1189 - 1197
[37] Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
Morgan, Gareth
Palumbo, Antonio
Dhanasiri, Sujith
Lee, Dawn
Weisel, Katja
Facon, Thierry
Delforge, Michel
Oriol, Albert
Zaki, Mohamed
Yu, Xin
Sternas, Lars
Jacques, Christian
Akehurst, Ron
Offner, Fritz
Dimopoulos, Meletios A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 820 - 823
[38] Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Qian, Xiaozhong
Dimopoulos, Meletios A.
Amatangelo, Michael
Bjorklund, Chad
Weisel, Katja C.
Ocio, Enrique M.
Yu, Xin
Peluso, Teresa
Sternas, Lars
Zaki, Mohamed
Moreau, Philippe
Thakurta, Anjan
BLOOD, 2017, 130
[39] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Attal, Michel
Richardson, Paul G.
Rajkumar, S. Vincent
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn P.
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth C.
LANCET, 2019, 394 (10214): : 2096 - 2107
[40] Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David S.
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin
Chen, Christine
Bahlis, Nizar
Oriol, Albert
Hansson, Markus
Kaiser, Martin
Anttila, Pekka
Raymakers, Reinier
Joao, Cristina
Cook, Gordon
Sternas, Lars
Biyukov, Tsvetan
Slaughter, Ana
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed
San-Miguel, Jesus
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (03) : 199 - 206

← 1 2 3 4 5 →